The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States.
 
Michael Marrone
Employment - SOBI; TeamHealth (I)
 
Robert Geller
Employment - IntegraConnect
 
Abiola Oladapo
Employment - SOBI
 
Purvi Suthar
Employment - CTI BioPharma Corp; SOBI
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Anupama Vasudevan
Employment - IntegraConnect; IntegraConnect
Stock and Other Ownership Interests - McKesson
 
Michael Vredenburg
Employment - SOBI
 
Jia Zeng
Employment - IntegraConnect
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Pharmaessentia; Roche/Genentech; Sierra Oncology; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmaessentia (Inst); Roche/Genentech (Inst)